Intracranial aneurysms
Conditions
Interventions
test group:large-size coils embolization
control group:normal-size coils embolization
Sponsors
Henan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 20-75 years old, male or female; 2.CTA/MRA/DSA is definitely diagnosed as an intracranial cystic aneurysm, including ruptured or unruptured aneurysm; 3. According to "Guide for the treatment of intracranial aneurysms", there are indications for intervention; 4. A round, circular (irregular shape but similar to round), oval (long diameter: short diameter = 2:1) aneurysm, including aneurysm with ascus; 5. The diameter of the aneurysm is 3-15mm; 6. Inclusive patients are willing to abide by the test plan and have the ability to visit regularly; 7. The patient can understand the content and significance of the trial and voluntarily participate in the trial and sign the consent form.
Exclusion criteria
Exclusion criteria: 1. The diameter of aneurysms larger than 15mm or smaller than 3mm; 2. Intracranial dissection or fusiform aneurysm, haemorrhagic aneurysm, pseudoaneurysm, and other special aneurysms; 3. Patients undergoing craniotomy, parent artery occlusion, blood flow guiding device therapy, and conservative treatment; 4. Aneurysms retreated after intravascular or surgical clipping for recurrence; 5. Aneurysm is related to intracranial arteriovenous malformation. 6. Not suitable for interventional treatment, patients who cannot tolerate anesthesia; 7. For those who have a history of fatal allergy to contrast agents, if they are non-fatal allergy, they must be carefully evaluated by a specialist before surgery to effectively prevent them; 8. Clear allergies or contraindications to local anesthetics or general anesthetics and patients who cannot tolerate surgery; 9.Having a systemic hemorrhage within 9.30 days, excluding intracranial hemorrhage such as subdural or epidural hemorrhage; 10. Major surgery such as femoral artery, aorta or carotid artery surgery in the first 30 days or in preparation for the next 90 days; 11. Patients with severe coagulation abnormalities, severe liver and kidney dysfunction, or with heart, respiratory system failure; 12. Patients who have been included in other studies that conflict with this study; 13. Patients who cannot understand the contents of the collaborative experiment or sign the informed consents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate of aneurysms; | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgery success rate;Postoperative immediate embolization;Postoperative retreatment rate;Aneurysmal rebleeding rate;operation time; | — |
Countries
China
Contacts
Public ContactJiangyu Xue
Henan Provincial People's Hospital
Outcome results
None listed